Quest Diagnostics Inc.

Company Snapshot

Founded: 1967
Entity Type: Public
Employees: 56,000
Region: U.S.
Revenue: $9,872.0 Millions
Revenue Year: 2024
Headquarter: New Jersey, U.S.
Key Geographics: U.S., Mexico, India, Ireland
Corporate Address: 500 Plaza Drive, Secaucus, New Jersey 07094, U.S. Tel. +1-973-520-2700 www.questdiagnostics.com

Company Overview

Quest Diagnostics is the U.S.'s major independent clinical laboratory operator, offering diagnostic testing and risk assessment services. In 2022, it experienced growth in prenatal genetic testing and pharma services. With approximately 49,000 employees, Quest provides NGS-based assays through Illumina and Thermo Fisher agreements. The company specializes in gene-based esoteric testing for various diseases and has a key alliance with UnitedHealthcare. Quest acquired Blueprint Genetics, enhancing its NGS capabilities for rare diseases. QuestDirect allows consumer-initiated testing, and a coalition with Grail supports the development of NGS-based cancer screening tests.

Quest Diagnostics provides a range of diagnostic tests, including general health profile tests, Women’s Health Tests, Men’s Health Tests, Heart Health Tests, and Sexual Health Tests. With 50 million tests conducted annually, Quest serves patients of all ages.

Financial Highlights (FY 2024)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
Operating Income: ***

This information is available for BCC Research members only.

Quest Diagnostics Inc. In Reports

Central Nervous System (CNS) Biomarkers: Technologies and Global Markets

Our detailed report on the Central Nervous System Biomarkers Markets is segmented based on by biomarker type, technology, disease, application, and region for the forecast 2025 through 2030.

Global Colorectal Cancer Screening and Diagnostics Market

BCC Research Report: Dive into Colorectal Cancer Screening and Diagnostics Market estimates, data is provided for 2021 and 2022 as historical years, 2023 as the base year, and forecasts extend through 2029.

Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

BCC Research Market Analyst says global market for Alzheimer’s disease therapeutics and diagnostics was valued at $9 billion in 2023. This market is expected to grow from $9.7 billion in 2024 to $19.6 billion by 2029

Company's Business Segments

  • Diagnostic Information Services (DIS) business : Discovery, Technology development and clinical validation of diagnostic tests
  • Diagnostic Solutions (DS) business : Risk assessment services business offers solutions for insurers, Healthcare IT businesses offers solutions for healthcare providers and payers

Applications/End User Industries

  • Physicians
  • Hospitals
  • Patients
  • Healthcare Providers
  • Government Agencies
  • Pharmaceutical Companies
AI Sentiment